Fred E. Fiedler

Suggest Changes
Learn More
BACKGROUND For patients with primary refractory or relapsed acute myeloid leukemia (AML), no treatment of choice has until now been defined to date. Cytarabine (Ara-C) is a key drug in the treatment(More)
  • 1